|DB00273||Topiramate||Topiramate is indicated for the following conditions:
- Monotherapy for partial onset or primary generalized tonic-clonic seizures in patients over 2 years of age.
- Adjunctive therapy for partial onset seizures or primary generalized tonic-clonic seizures for adult and pediatric patients.
- Adjunctive therapy for seizures associated with Lennox-Gastaut syndrome in patients over 2 years of age.
- Prophylaxis of migraine headache in adults.[FDA label]
A seizure is an abnormal, unregulated electrical discharge occurring in the brain's cortical gray matter. This electrical response produces a transient interruption in the normal brain function which in order produces altered awareness, abnormal sensations, focal involuntary movements or convulsions. The type of seizure can be classified according to the type of onset followed by a type of seizure.[L5548]
A migraine headache is a [ulsating or throbbing pain that can be presented in one of both sides of the head and it can be worsened by external stimuli such as physical activity, light, sounds, and odors.[L5551]
Topiramate has been commonly investigated and used off-label for weight reduction in patients with obesity or diabetes.[A175240]|
|DB00740||Riluzole||For the treatment of amyotrophic lateral sclerosis (ALS, Lou Gehrig's Disease)|
|DB00959||Methylprednisolone||Adjunctive therapy for short-term administration in rheumatoid arthritis.|
|DB00989||Rivastigmine||For the treatment of mild to moderate dementia associated with Parkinson's disease or of the Alzheimer's type.|
|DB01037||Selegiline||Monotherapy for initial treatment of Parkinson's disease, as well as an adjunct therapy in patients with a decreased response to levodopa/carbadopa. Also used for the palliative treatment of mild to moderate Alzheimer's disease and at higher doses, for the treatment of depression.|
|DB01166||Cilostazol||Indicated for the alleviation of symptoms of intermittent claudication (pain in the legs that occurs with walking and disappears with rest).|
|DB01367||Rasagiline||For the treatment of the signs and symptoms of idiopathic Parkinsons disease as initial monotherapy and as adjunct therapy to levodopa.|
|DB01520||Tenocyclidine||Because of its high affinity for the phencyclidine binding site on the NMDA receptor, the 3H radiolabelled form of tenocyclidine is widely used in research into NMDA receptors.|
|DB04864||Huperzine A||Investigated for use/treatment in alzheimer's disease.|
|DB05010||SGS-742||Investigated for use/treatment in alzheimer's disease, attention deficit/hyperactivity disorder (ADHD), memory loss, and schizophrenia and schizoaffective disorders.|
|DB05660||D-JNKI-1||Investigated for use/treatment in hearing loss.|
|DB06230||Nalmefene||Indicated for the reduction of alcohol consumption in adult patients with alcohol dependence who have a high drinking risk level (DRL), without physical withdrawal symptoms and who do not require immediate detoxification [L1024].
Indicated for the complete or partial reversal of opioid drug effects, including respiratory depression - induced by either natural or synthetic opioids - or in the management of known or suspected opioid overdose [FDA Label].|
|DB06444||Dexanabinol||Investigated for use/treatment in traumatic brain injuries and neurologic disorders.|
|DB06458||Remacemide||Investigated for use/treatment in epilepsy, huntington's disease, and parkinson's disease.|
|DB06470||Clomethiazole||Investigated for use/treatment in strokes.|
|DB06479||Propentofylline||Investigated for use/treatment in alzheimer's disease.|
|DB07744||Z-Val-Ala-Asp fluoromethyl ketone||Not Available|
|DB09210||Piracetam||Indicated in adult patients suffering from myoclonus of cortical origin, irrespective of aetiology, and should be used in combination with other anti-myoclonic therapies [L1125].|
|DB12116||Epigallocatechin gallate||Not Available|
|DB14644||Methylprednisolone hemisuccinate||Not Available|
|DB01430||Almitrine||For the treatment of chronic obstructive pulmonary disease.|
|DB12243||Edaravone||Indicated for improving neurological symptoms and damage from acute ischemic stroke and delaying disease progression of ALS.|